Edition:
India

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

537.10INR
2:42pm IST
Change (% chg)

Rs-14.20 (-2.58%)
Prev Close
Rs551.30
Open
Rs555.10
Day's High
Rs555.90
Day's Low
Rs536.20
Volume
735,205
Avg. Vol
2,799,148
52-wk High
Rs564.00
52-wk Low
Rs295.03

Chart for

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

BRIEF-Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil

* CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS

29 Dec 2017

BRIEF-Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA

* CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE

13 Dec 2017

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

07 Dec 2017

Sensex snaps four-session losing streak; Infosys gains

Indian shares snapped a four-session losing streak to end higher on Monday, as Infosys Ltd climbed on the appointment of a new CEO and hopes that the software services firm would move past a costly boardroom spat.

04 Dec 2017

BUZZ-India's Biocon hits record high on U.S. FDA approval for generic cancer drug Ogivri

** Biocon Ltd jumps as much as 13.8 pct to hit a record high of 509.00 rupees

04 Dec 2017

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

02 Dec 2017

BUZZ-India's Biocon hits record high; EU regulator OKs marketing applications for generic cancer drugs

** Biocon Ltd jumped as much as 3.6 pct to touch a record high of 447.60 rupees

01 Dec 2017

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

30 Nov 2017

BRIEF-Biocon ‍launches Krabeva in India​

* Launches Krabeva - biosimilar Bevacizumab for treating several types of cancer in India​

23 Nov 2017

BUZZ-India's Biocon jumps on green signal for U.S. export

** Shares of Biocon Ltd surge as much as 6.4 pct, their biggest intraday pct gain since Nov. 17

20 Nov 2017

Earnings vs. Estimates

No consensus analysis data available.